JP7649560B2 - 新規ｆｙｎ及びｖｅｇｆｒ２キナーゼ阻害剤 - Google Patents

新規ｆｙｎ及びｖｅｇｆｒ２キナーゼ阻害剤 Download PDF

Info

Publication number
JP7649560B2
JP7649560B2 JP2022534848A JP2022534848A JP7649560B2 JP 7649560 B2 JP7649560 B2 JP 7649560B2 JP 2022534848 A JP2022534848 A JP 2022534848A JP 2022534848 A JP2022534848 A JP 2022534848A JP 7649560 B2 JP7649560 B2 JP 7649560B2
Authority
JP
Japan
Prior art keywords
ethyl
pyrazol
phenyl
benzamide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505684A (ja
JPWO2021116005A5 (enExample
Inventor
クラウディオ ロヴァティ、ルチオ
カゼッリ、ジャンフランコ
アルトゥシ、ロベルト
メンヌーニ、ラウラ
コラーチェ、ファブリツィオ
マンデッリ、ステファノ
ボヴィーノ、クララ
マガラチー、フィリッポ
ブッツィ、ベネデッタ
Original Assignee
ロッタファーム・バイオテック・エッセ・エッレ・エッレ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロッタファーム・バイオテック・エッセ・エッレ・エッレ filed Critical ロッタファーム・バイオテック・エッセ・エッレ・エッレ
Publication of JP2023505684A publication Critical patent/JP2023505684A/ja
Publication of JPWO2021116005A5 publication Critical patent/JPWO2021116005A5/ja
Application granted granted Critical
Publication of JP7649560B2 publication Critical patent/JP7649560B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022534848A 2019-12-09 2020-12-07 新規ｆｙｎ及びｖｅｇｆｒ２キナーゼ阻害剤 Active JP7649560B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/084287 2019-12-09
PCT/EP2019/084287 WO2021115560A1 (en) 2019-12-09 2019-12-09 New fyn and vegfr2 kinase inhibitors
PCT/EP2020/084847 WO2021116005A1 (en) 2019-12-09 2020-12-07 New fyn and vegfr2 kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2023505684A JP2023505684A (ja) 2023-02-10
JPWO2021116005A5 JPWO2021116005A5 (enExample) 2023-12-07
JP7649560B2 true JP7649560B2 (ja) 2025-03-21

Family

ID=69105765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534848A Active JP7649560B2 (ja) 2019-12-09 2020-12-07 新規ｆｙｎ及びｖｅｇｆｒ２キナーゼ阻害剤

Country Status (5)

Country Link
EP (1) EP4073057B1 (enExample)
JP (1) JP7649560B2 (enExample)
CN (1) CN115279747B (enExample)
ES (1) ES2972638T3 (enExample)
WO (2) WO2021115560A1 (enExample)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517447A (ja) 1998-11-06 2003-05-27 ビーエーエスエフ アクチェンゲゼルシャフト 三環式ピラゾール誘導体
JP2009541480A (ja) 2006-06-30 2009-11-26 アストラゼネカ アクチボラグ 癌の治療において有用なピリミジン誘導体
JP2010529990A (ja) 2007-06-15 2010-09-02 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤およびそれを使用するための方法
JP2011506454A (ja) 2007-12-13 2011-03-03 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
US20130172353A1 (en) 2011-12-28 2013-07-04 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
JP2018507857A (ja) 2015-03-18 2018-03-22 ロッタファーム・バイオテック・エッセ・エッレ・エッレ 新規ｆｙｎキナーゼ阻害剤
JP2018531916A (ja) 2015-09-09 2018-11-01 ウォーレン シー． ラウ， 新規のｆｙｎキナーゼ阻害剤の方法、組成物、及び使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1848694T3 (da) 2005-02-07 2010-01-25 Hoffmann La Roche Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517447A (ja) 1998-11-06 2003-05-27 ビーエーエスエフ アクチェンゲゼルシャフト 三環式ピラゾール誘導体
JP2009541480A (ja) 2006-06-30 2009-11-26 アストラゼネカ アクチボラグ 癌の治療において有用なピリミジン誘導体
JP2010529990A (ja) 2007-06-15 2010-09-02 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤およびそれを使用するための方法
JP2011506454A (ja) 2007-12-13 2011-03-03 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
US20130172353A1 (en) 2011-12-28 2013-07-04 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
JP2018507857A (ja) 2015-03-18 2018-03-22 ロッタファーム・バイオテック・エッセ・エッレ・エッレ 新規ｆｙｎキナーゼ阻害剤
JP2018531916A (ja) 2015-09-09 2018-11-01 ウォーレン シー． ラウ， 新規のｆｙｎキナーゼ阻害剤の方法、組成物、及び使用

Also Published As

Publication number Publication date
WO2021115560A1 (en) 2021-06-17
CN115279747A (zh) 2022-11-01
ES2972638T3 (es) 2024-06-13
CN115279747B (zh) 2024-11-05
EP4073057B1 (en) 2023-11-29
WO2021116005A8 (en) 2022-07-14
WO2021116005A1 (en) 2021-06-17
JP2023505684A (ja) 2023-02-10
US20230061118A1 (en) 2023-03-02
EP4073057A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
TWI801372B (zh) 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
JP6750806B2 (ja) Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体
EP2970120B1 (en) Novel pyrimidine and pyridine compounds and their usage
US11434245B2 (en) WNT pathway modulators
KR101571720B1 (ko) 신규 Syk 억제제로서의 치환된 피리도피라진
TW201900632A (zh) N-(氮雜芳基)環內醯胺-1-甲醯胺衍生物及其製備方法和應用
TWI836960B (zh) 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
JP2012502986A (ja) Ｐ２ｘ３受容体活性のモジュレーター
KR20150108372A (ko) 단백질 키나아제의 억제제로서의 아자인돌 유도체
KR20240005892A (ko) Lpa 수용체 길항제 및 이의 용도
Xu et al. Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3, 3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
WO2013100672A1 (ko) 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체
TWI434840B (zh) 吡唑啶－３－酮衍生物
JP2022502425A (ja) Ｎａｄｐｈオキシダーゼ阻害剤としての新規化合物
KR20140086002A (ko) Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체
CA2887887A1 (en) Pyrazolopyridine derivatives as ttx-s blockers
JP2024509795A (ja) アミノピリミジン化合物及びその使用方法
Jin et al. Synthesis and biological evaluation of 1-substituted-3 (5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl) pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors
JP7649560B2 (ja) 新規ｆｙｎ及びｖｅｇｆｒ２キナーゼ阻害剤
US12509446B2 (en) FYN and VEGFR2 kinase inhibitors
US20060074244A1 (en) Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway
CA2959290A1 (en) 2-aminothiazole derivative or salt thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250303

R150 Certificate of patent or registration of utility model

Ref document number: 7649560

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150